CLINICAL TRIALS PROFILE FOR AGENERASE

All Clinical Trials for AGENERASE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00005017 ↗	Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment	Unknown status	Glaxo Wellcome	Phase 4	1969-12-31	The purpose of this study is to see how effective and safe it is to give 1 of the 3 following treatments to patients who may not have received anti-HIV treatment: 1) lamivudine (3TC)/abacavir (ABC)/stavudine (d4T); 2) 3TC/ABC/efavirenz (EFV); or 3) 3TC/ABC/amprenavir (APV)/ritonavir (RTV).
NCT00006591 ↗	Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment	Unknown status	Gathe, Joseph, M.D.	N/A	1969-12-31	The purpose of this study is to determine if treatment with an anti-HIV drug containing ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who have failed an anti-HIV drug treatment containing nelfinavir.
NCT00624195 ↗	Clinical Trial of CNS-targeted HAART (CIT2)	Completed	National Institute of Mental Health (NIMH)	Phase 2/Phase 3	2007-03-01	CIT2 is a strategy for targeting HAART (Highly Active Antiretroviral Therapy) to the CNS (Central Nervous System) in patients with HIV associated neurocognitive impairment (HNCI). The primary goal of this study is to evaluate the effectiveness of CNS-targeted (CNS-T) as compared to non-CNS-targeted (non-CNS-T) HAART in treating HNCI globally and in different domains of functioning known to be affected by HIV. It is hypothesized that participants in the CNS-T arm will have greater improvement in neurocognitive functioning than those in the non-CNS-T arm. The secondary goal of the study is to compare participants assigned to CNS-T and non-CNS-T HAART on measures of CNS and systemic HIV suppression (undetectable CSF and plasma VL). It is also hypothesized that although CSF viral suppression will be more frequent in the CNS-T arm, plasma viral suppression will be similar in the two treatment arms.
NCT00624195 ↗	Clinical Trial of CNS-targeted HAART (CIT2)	Completed	National Institutes of Health (NIH)	Phase 2/Phase 3	2007-03-01	CIT2 is a strategy for targeting HAART (Highly Active Antiretroviral Therapy) to the CNS (Central Nervous System) in patients with HIV associated neurocognitive impairment (HNCI). The primary goal of this study is to evaluate the effectiveness of CNS-targeted (CNS-T) as compared to non-CNS-targeted (non-CNS-T) HAART in treating HNCI globally and in different domains of functioning known to be affected by HIV. It is hypothesized that participants in the CNS-T arm will have greater improvement in neurocognitive functioning than those in the non-CNS-T arm. The secondary goal of the study is to compare participants assigned to CNS-T and non-CNS-T HAART on measures of CNS and systemic HIV suppression (undetectable CSF and plasma VL). It is also hypothesized that although CSF viral suppression will be more frequent in the CNS-T arm, plasma viral suppression will be similar in the two treatment arms.
NCT00624195 ↗	Clinical Trial of CNS-targeted HAART (CIT2)	Completed	University of California, San Diego	Phase 2/Phase 3	2007-03-01	CIT2 is a strategy for targeting HAART (Highly Active Antiretroviral Therapy) to the CNS (Central Nervous System) in patients with HIV associated neurocognitive impairment (HNCI). The primary goal of this study is to evaluate the effectiveness of CNS-targeted (CNS-T) as compared to non-CNS-targeted (non-CNS-T) HAART in treating HNCI globally and in different domains of functioning known to be affected by HIV. It is hypothesized that participants in the CNS-T arm will have greater improvement in neurocognitive functioning than those in the non-CNS-T arm. The secondary goal of the study is to compare participants assigned to CNS-T and non-CNS-T HAART on measures of CNS and systemic HIV suppression (undetectable CSF and plasma VL). It is also hypothesized that although CSF viral suppression will be more frequent in the CNS-T arm, plasma viral suppression will be similar in the two treatment arms.

Clinical Trial Conditions for AGENERASE

Condition Name

Condition Name for AGENERASE
Intervention	Trials
HIV Infections	3

Condition MeSH

Condition MeSH for AGENERASE
Intervention	Trials
HIV Infections	3

Clinical Trial Locations for AGENERASE

Trials by Country

Trials by Country for AGENERASE
Location	Trials
United States	6

Trials by US State

Trials by US State for AGENERASE
Location	Trials
New York	1
Missouri	1
Maryland	1
California	1
Texas	1

Clinical Trial Progress for AGENERASE

Clinical Trial Phase

Clinical Trial Phase for AGENERASE
Clinical Trial Phase	Trials
Phase 4	1
Phase 2/Phase 3	1
N/A	1

Clinical Trial Status

Clinical Trial Status for AGENERASE
Clinical Trial Phase	Trials
Unknown status	2
Completed	1

Clinical Trial Sponsors for AGENERASE

Sponsor Name

Sponsor Name for AGENERASE
Sponsor	Trials
Glaxo Wellcome	1
Gathe, Joseph, M.D.	1
National Institute of Mental Health (NIMH)	1

Sponsor Type

Sponsor Type for AGENERASE
Sponsor	Trials
Other	2
NIH	2
Industry	1

Last updated: May 8, 2026

AGENERASE (amprenavir): clinical trials update, market analysis, and projection

What is AGENERASE and where does it sit in the HIV market?

AGENERASE is the brand name for amprenavir, an HIV-1 protease inhibitor (PI). In-market PI competition has narrowed materially since protease inhibitors with better dosing convenience (and later, more tolerable regimens) gained share. Amprenavir itself was historically positioned as a PI option that later faced preference shifts toward other PIs and regimens built around integrase inhibitors.

Commercial reality: In mature HIV therapy markets, legacy PIs typically sustain only niche use unless they are embedded in specific guideline pathways, fixed-dose combinations, or payer-favored formularies. Amprenavir’s trajectory is consistent with a mature, declining product life-cycle following class and regimen shifts.

---

Which clinical trials and label-relevant studies still matter for AGENERASE?

No new, widely cited late-stage registration trials for amprenavir/AGENERASE are typically active in the post–integrase era. For decision-grade analysis, the practical lens is whether any ongoing or newly reported Phase 3/registrational programs exist, and whether any recent publications materially change safety, resistance, or dosing.

Current clinical-trials footprint (decision-grade framing):

• Registrational new cohorts: not a dominant ongoing theme for amprenavir in recent years.
• Ongoing studies (typical for legacy antiretrovirals): if present, tend to be smaller pharmacokinetic, interaction, formulation, or real-world resistance sub-studies rather than definitive Phase 3 efficacy work.
• Actionable use case: AGENERASE-related clinical value today is mainly comparative historical data (efficacy, resistance profile) rather than new Phase 3 outcomes.

Implication for R&D diligence: For investors or partners, the path to meaningful incremental clinical value is unlikely to be “new trials for AGENERASE.” The more plausible angle is historical data utility for combination logic, resistance interpretation, or therapeutic switching evidence in subpopulations where PI-based strategies persist.

---

What is the competitive landscape for protease inhibitors versus amprenavir?

Protease inhibitor utilization has shifted within ART sequencing due to regimen durability, tolerability, and clinician preference for integrase-based backbones. That shift compresses the opportunity set for older PIs like amprenavir.

Key competitive pressures affecting AGENERASE demand:

• Class migration: widespread adoption of integrase strand transfer inhibitor (INSTI)-based regimens reduced PI share.
• Dosing convenience and tolerability: newer PI options have more favorable real-world adherence profiles.
• Resistance management: PI choice is increasingly optimized around resistance testing and simplified regimen strategies.

Commercial consequence: Even if amprenavir remains clinically usable, market expansion is structurally constrained.

---

How does AGENERASE compare on pricing and access levers that drive HIV payer decisions?

Mature HIV drug channels are shaped by:

• Formulary access (national and managed care)
• Tender and contract pricing
• Generic displacement risk and timing
• Fixed-dose combination availability that reduces pill burden

For AGENERASE specifically, the decision-relevant market behavior is that older brands with PI ingredients commonly face:

• generic erosion over time,
• channel consolidation into the most cost-effective PI options,
• and payer preferences for regimens that reduce pharmacy and adherence friction.

---

What does market analysis imply for AGENERASE revenues and volume?

AGENERASE’s market outlook is best modeled as a legacy PI with limited growth. The drivers are:

• No new late-stage efficacy expansion
• Sustained but small residual demand where PIs remain clinically selected
• Long-term pressure from integrase-based and newer PI regimens
• Generic penetration reducing net brand revenue

Projection logic for a mature legacy antiretroviral:

1. Base demand is residual: patients on older PI regimens or those with specific resistance histories.
2. Decline rate is driven by regimen switching, prescriber preferences, and payer formularies favoring lower-cost alternatives.
3. Upside is capped because legacy PIs do not typically regain dominance without new evidence or superior dosing.

---

Market projection for AGENERASE (2026-2031): scenario model

Because AGENERASE is a legacy product with constrained clinical growth, the projection should be treated as a declining share model with possible stabilization where formularies or resistance profiles sustain usage.

Scenario bands (global net product sales, indexed): | Year | Conservative (Index) | Base (Index) | Aggressive (Index) | |---|---:|---:|---:| | 2026 | 100 | 100 | 100 | | 2027 | 92 | 88 | 95 | | 2028 | 85 | 78 | 90 | | 2029 | 78 | 70 | 84 | | 2030 | 72 | 63 | 79 | | 2031 | 66 | 57 | 74 |

Interpretation for investors:

• Base case: continued decline in net brand revenues through 2031 driven by switching away from legacy PIs and pricing compression from lower-cost alternatives.
• Conservative case: slower erosion if residual PI cohorts remain larger than expected or if local formularies retain amprenavir longer.
• Aggressive case: moderate stabilization only if payer access and clinical inertia sustain use, not from new competitive breakthroughs.

---

What is the key risk to the downside projection?

The primary “less bad” outcome for AGENERASE is not new efficacy but access persistence:

• longer retention on formularies in certain geographies or cohorts,
• slow regimen switching due to contraindications or resistance complexity,
• or continued availability in settings where alternatives are not optimal.

---

What is the key upside path for AGENERASE?

Upside is limited but could occur if any of the following become materially true:

• new clinical evidence expands use into a niche where a PI backbone remains preferred,
• new treatment sequencing guidance explicitly supports amprenavir-based strategies in a defined subgroup,
• or payer contracting sustains price competitiveness relative to alternative PIs.

Absent that, AGENERASE remains a “hold position” product rather than a growth product.

---

Business implications: where to deploy resources instead of betting on AGENERASE growth

For R&D and licensing strategy, the market math is straightforward:

• Clinical trial investment for AGENERASE itself is unlikely to generate a new growth runway.
• Partnership strategy should focus on life-cycle management angles (historical data, resistance interpretation, drug interaction evidence) rather than new label expansion.
• Investment thesis alignment: If the goal is growth, allocate capital to platforms with registrational momentum (new drug modalities, combination products, or next-generation ART strategies).

---

Key Takeaways

• AGENERASE (amprenavir) sits in the mature protease inhibitor segment with constrained growth due to regimen migration toward integrase-based therapies.
• Clinical development relevance is primarily historical for AGENERASE; the label-expansion pattern typical for newer ART breakthroughs is not the dominant driver for this legacy PI.
• Market outlook to 2031 is best modeled as continued decline with possible stabilization, driven by regimen switching, payer contracting, and cost compression from alternatives and generics.
• The downside-to-base spread depends on how long residual PI cohorts remain on amprenavir and how formularies retain it across geographies and payer segments.

---

FAQs

1. Is AGENERASE expected to gain market share in the INSTI era?
   No. The structural shift toward INSTI-based backbones limits PI share expansion for older PIs.

2. Do new Phase 3 trials drive AGENERASE’s near-term outlook?
   Not typically; AGENERASE is not positioned as a registrational pipeline candidate in recent-era ART development.

3. What most affects AGENERASE revenue erosion?
   Payer formulary replacement, patient switching to preferred regimens, and cost competition from lower-priced PI options and generics.

4. Can AGENERASE stabilize in certain cohorts?
   Yes. Residual use can persist where resistance profiles, tolerability constraints, or contracting keep older PI options in place.

5. What is the most realistic upside scenario for AGENERASE?
   Sustained access and cohort retention rather than new clinical breakthrough outcomes.

---

References

[1] FDA. AGENERASE (amprenavir) Drug Label. (Accessed via FDA labeling archives).
[2] ClinicalTrials.gov. Search results for amprenavir / AGENERASE.
[3] WHO. Guidelines for the use of antiretroviral agents for treating and preventing HIV infection (latest relevant editions).
[4] IAS-USA. International Antiviral Society-USA recommendations for use of antiretroviral agents in adults and adolescents (latest relevant recommendations).